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Varlilumab is a human IgG1 agonist anti-CD27 antibody
designed to activate T cells through CD27 costimulation.
Preclinical studies have shown that Varlilumab efficiently
activates human T cells when combined with T cell recep-
tor stimulation, enhances antigen specific CD8 T cell
responses in human CD27 transgenic mice when com-
bined with vaccination, and mediates anti-tumor activity
in these mice when challenged with syngeneic tumors. A
multi-dose, dose-escalation/expansion trial of Varlilumab
in patients with advanced solid tumors (n = 56) or lym-
phoma (n = 24) has demonstrated a good safety profile
with no MTD reached through the 10 mg/kg dose level.
Evidence of clinical activity includes a complete response
in a treatment-refractory Stage IV Hodgkin’s patient
(remains in remission at 12.9 months); a renal cell carci-
noma (RCC) patient with a partial response (ongoing at
3.8 months); an additional RCC patient with extended
stable disease (ongoing at 22.4+ months); and 12 addi-
tional patients with stable disease (range: 2.7+ to 14
months). We performed extensive correlative immune
monitoring from serum and peripheral blood cells, parti-
cularly in melanoma and RCC patients. Differential gene
expression analysis was assessed pre- and post-treatment
by hybridizing RNA isolated from whole blood PAXgene
RNA tubes onto Illumina HT-12 microarrays. Transcrip-
tomic analysis showed significant impact of Varlilumab on
immunological pathways, including T cell receptor signal-
ing that was observed at early time points (day 2 and day
8 post treatment). Interestingly, these changes were most
significant at low dose levels (0.1 and 0.3 mg/kg), however,
a larger sample size would be required to confirm these
results. Varlilumab administration was associated with
enhanced T cell activity by evaluation of activation mar-
kers and functional analysis using IFN-g Elispot. In parti-
cular, evaluation of response to peptides derived from
melanoma antigens in selected patients showed evidence
that Varlilumab promoted CD8+ T cell function against
melanoma antigens. Specifically, expanded responses were
detected to epitopes from gp100 and MART-1, while de
novo responses to epitopes MAGE-A1, NY-ESO-1 and
gp100 were evident. These responses were confirmed by
MHC-multimer staining. These data, and our previous
analyses demonstrating a transient increase in pro-inflam-
matory cytokines (IP-10, IL-6, MCP-1), up-regulation of
HLA-DR expression on T cells, increase in NK cell
numbers, and decrease in regulatory T cells in response to
Varlilumab treatment, show a pattern consistent with
CD27 costimulation. These results, together with our pre-
clinical data, provide the rationale for initiating clinical
studies of Varlilumab in combination with therapies such
as vaccines, checkpoint inhibitors and targeted therapies.
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